Metastatic Hormone-Sensitive Prostate Cancer

A blood test for men at the time of a metastatic prostate cancer diagnosis may predict treatment response and survival, according to study results.

Men with bone pain at diagnosis of metastatic, hormone-resistant prostate cancer had shorter survival than men without bone pain, according to study results.

Several practice-changing clinical trials in recent years have led to the understanding that combination treatments are most effective for patients with advanced prostate cancer.

Tanya Dorff, MD, section chief of the genitourinary disease program at City of Hope, spoke with Healio about results from the ARASENS trial presented at the 2022 ASCO Genitourinary Cancers Symposium.